Showing 5421-5440 of 8668 for: Cochrane Systematic Reviews Back
- Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis
Cochrane Systematic Reviews, 27-May-2008
Omega-3 fatty acids (n-3, fish oil) have been shown to have anti-inflammatory properties. Therefore, n-3 therapy may be beneficial in chronic inflammatory disorders such as ulcerative colitis.
- Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration
Cochrane Systematic Reviews, 9-Apr-2015
Evidence from animal models and observational studies in humans has suggested that there is an inverse relationship between dietary intake of omega 3 long-chain polyunsaturated fatty acids (LCPUFA) and risk of developing age-related macular degeneration (
- Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease
Cochrane Systematic Reviews, 18-Dec-2019
Polyunsaturated fatty acid (PUFA) supplements, involving omega-3 and/or omega-6 components, have been proposed as a therapy for dry eye. Omega-3 PUFAs exist in both short- (alpha-linolenic acid [ALA]) and long-chain (eicosapentaenoic acid [EPA] and docosa
- Omega‐3 fatty acid addition during pregnancy
Cochrane Systematic Reviews, 15-Nov-2018
Higher intakes of foods containing omega-3 long-chain polyunsaturated fatty acids (LCPUFA), such as fish, during pregnancy have been associated with longer gestations and improved perinatal outcomes. This is an update of a review that was first published
- Omega‐3 fatty acid supplementation for cystic fibrosis
Cochrane Systematic Reviews, 10-Apr-2020
Studies suggest that a diet rich in omega-3 essential fatty acids may have beneficial anti-inflammatory effects for chronic conditions such as cystic fibrosis. This is an updated version of a previously published review.
- Omega-3 fatty acids for bipolar disorder
Cochrane Systematic Reviews, 2-Nov-2008
Bipolar disorder is a complex psychiatric disorder and is amongst the top thirty causes of worldwide disability. Mood stabilisers are the primary pharmacological intervention, both in the treatment of acute episodes and in prophylaxis. There is, however,
- Omega‐3 fatty acids for depression in adults
Cochrane Systematic Reviews, 24-Nov-2021
Major depressive disorder (MDD) is highly debilitating, difficult to treat, has a high rate of recurrence, and negatively impacts the individual and society as a whole. One potential treatment for MDD is n-3 polyunsaturated fatty acids (n-3PUFAs), also kn
- Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease
Cochrane Systematic Reviews, 18-Nov-2018
Maintaining long-term vascular access patency is necessary for high quality haemodialysis (HD) treatment of patients with the terminal and most serious stage of chronic kidney disease (CKD) - end-stage kidney disease (ESKD). Oral supplementation with omeg
- Omega-3 fatty acids for intermittent claudication
Cochrane Systematic Reviews, 3-Jul-2013
Omega-3 fatty acids have been used in the treatment and prevention of coronary artery disease although current evidence suggests they may be of limited benefit. Peripheral arterial disease and coronary artery disease share a similar pathogenesis so omega-
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
Cochrane Systematic Reviews, 29-Feb-2020
Omega-3 polyunsaturated fatty acids from oily fish (long-chain omega-3 (LCn3)), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha-linolenic acid (ALA)) may benefit cardiovascular health. Guidelines recomm
- Omega‐3 fatty acids for the treatment of dementia
Cochrane Systematic Reviews, 11-Apr-2016
Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish and plant sources are commonly considered as a promising non-medical alternative to improve brain functions and slow down the progression of dementia. This assumption is mostly based on finding
- Omega-3 fatty acids supplementation for autism spectrum disorders (ASD)
Cochrane Systematic Reviews, 31-Oct-2011
It has been suggested that impairments associated with autism spectrum disorders (ASD) may be partially explained by deficits of omega-3 fatty acids, and that supplementation of these essential fatty acids may lead to improvement of symptoms.
- Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus
Cochrane Systematic Reviews, 4-Nov-2008
People with type 2 diabetes mellitus are at increased risk from cardiovascular disease. Dietary omega-3 polyunsaturated fatty acids (PUFAs) are known to reduce triglyceride levels, but their impact on cholesterol levels, glycemic control and vascular outc
- Omega‐6 fats for the primary and secondary prevention of cardiovascular disease
Cochrane Systematic Reviews, 29-Nov-2018
Omega-6 fats are polyunsaturated fats vital for many physiological functions, but their effect on cardiovascular disease (CVD) risk is debated.
- Omentoplasty for oesophagogastrostomy after oesophagectomy
Cochrane Systematic Reviews, 1-Oct-2014
Oesophagectomy followed by oesophagogastrostomy is the preferred treatment for early-stage oesophageal cancer. It carries the risk of anastomotic leakage after oesophagogastric anastomosis, which causes considerable morbidity and mortality and is one of t
- Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 6-Mar-2019
Chronic obstructive pulmonary disease (COPD) is a respiratory condition causing accumulation of mucus in the airways, cough, and breathlessness; the disease is progressive and is the fourth most common cause of death worldwide. Current treatment strategie
- Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media
Cochrane Systematic Reviews, 13-Dec-2013
Acute otitis media (AOM) is a common problem in children, for which amoxicillin, with or without clavulanate, is frequently prescribed as a treatment of choice. The conventional recommendation is either three or four daily doses. However, nowadays it is f
- Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
Cochrane Systematic Reviews, 16-Jul-2013
In the initial treatment of venous thromboembolism (VTE) low molecular weight heparin (LMWH) is administered once or twice daily. A once daily treatment regimen is more convenient for the patient and may optimise home treatment. However, it is not clear w
- Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
Cochrane Systematic Reviews, 24-Aug-2018
Three classes of inhaler medication are used to manage chronic obstructive pulmonary disease (COPD): long-acting beta2-agonists (LABA); long-acting muscarinic antagonists (LAMA); and inhaled corticosteroids (ICS). To encourage patient adherence, two class
- Once‐daily versus multiple‐daily dosing with intravenous aminoglycosides for cystic fibrosis
Cochrane Systematic Reviews, 4-Sep-2019
People with cystic fibrosis, who are chronically colonised with the organism Pseudomonas aeruginosa, often require multiple courses of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations. The properties of aminoglycosides
